When compared to wild-type CD5-CAR-T, CRISPR-Cas9-based KO CD5-CAR T enhances anti-tumor efficacy with improved CAR-T activation and proliferation, which may be driven in part by reduced fratricide [75]. Here, CD5 is linked to neoplasm.